Cochrane · systematic review · CD004267
Antibiotics for ventilator‐associated pneumonia
Arthur, LE, Kizor, RS, Selim, AG, et al. · Cochrane Database of Systematic Reviews · 2016 · Cochrane Library
Acute Respiratory InfectionsAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
9
current version
GRADE rated
9
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 2 · 22.2%Low 1 · 11.1%Moderate 6 · 66.7%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Monotherapy compared to combination therapy for ventilator‐associated pneumonia
Population: Ventilator‐associated pneumonia
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
All‐cause mortality; Monotherapy vs combination therapy | OR 0.97 [0.73, 1.3] | 4 studies · 1163 participants | Moderate Downgraded: imprecision, inconsistency |
Clinical cure (ITT) Monotherapy vs combination therapy | OR 0.88 [0.56, 1.36] | 2 studies · 350 participants | Very low Downgraded: imprecision, inconsistency |
Clinical cure (CE) Monotherapy vs combination therapy | OR 0.97 [0.56, 1.68] | 2 studies · 228 participants | Very low Downgraded: imprecision, inconsistency |
Adverse events Monotherapy vs combination therapy | OR 0.93 [0.68, 1.26] | 2 studies · 921 participants | Moderate Downgraded: imprecision, inconsistency |
Length of ICU stay Monotherapy vs combination therapy | no estimate extracted | 2 studies · 813 participants | Moderate Downgraded: imprecision, inconsistency |
Carbapenems compared to non‐carbapenems for ventilator‐associated pneumonia
Population: Ventilator‐associated pneumonia
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
All‐cause mortality; Carbapenems vs non‐carbapenems | OR 0.59 [0.3, 1.19] | 1 study · 253 participants | Moderate Downgraded: risk of bias, imprecision |
Clinical cure (ITT) Carbapenems vs non‐carbapenems | OR 1.53 [1.11, 2.12] | 3 studies · 598 participants | Moderate Downgraded: risk of bias, imprecision |
Clinical cure (CE) Carbapenems vs non‐carbapenems | OR 2.29 [1.19, 4.43] | 2 studies · 163 participants | Moderate Downgraded: risk of bias, imprecision |
Adverse events Carbapenems vs non‐carbapenems | OR 0.78 [0.56, 1.09] | 3 studies · 1510 participants | Low Downgraded: risk of bias, imprecision |